Literature DB >> 28516074

An Updated Nationwide Epidemiology of Primary Brain Tumors in Republic of Korea, 2013.

Yun-Sik Dho1, Kyu-Won Jung2, Johyun Ha2, Youngbeom Seo3, Chul-Kee Park1, Young-Joo Won2, Heon Yoo4.   

Abstract

BACKGROUND: This report aims to provide accurate nationwide epidemiologic data on primary brain and central nervous system (CNS) tumors in the Republic of Korea. We updated the data by analyzing primary brain and CNS tumors diagnosed in 2013 using the data from the national cancer incidence database.
METHODS: Data on primary brain and CNS tumors diagnosed in 2013 were collected from the Korean Central Cancer Registry. Crude and age-standardized rates were calculated in terms of gender, age, and histological type.
RESULTS: A total of 11,827 patients were diagnosed with primary brain and CNS tumors in 2013. Brain and CNS tumors occurred in females more often than in males (female:male, 1.70:1). The most common tumor was meningioma (37.3%). Pituitary tumors (18.0%), gliomas (12.7%), and nerve sheath tumors (12.3%) followed in incidence. Glioblastomas accounted for 41.8% of all gliomas. In children (<19 years), sellar region tumors (pituitary and craniopharyngioma), embryonal/primitive/medulloblastoma, and germ cell tumors were the most common tumors.
CONCLUSION: This study should provide valuable information regarding the primary brain tumor epidemiology in Republic of Korea.

Entities:  

Keywords:  Brain; Central nervous system; Epidemiology; Korea; Registries; Tumors

Year:  2017        PMID: 28516074      PMCID: PMC5433946          DOI: 10.14791/btrt.2017.5.1.16

Source DB:  PubMed          Journal:  Brain Tumor Res Treat        ISSN: 2288-2405


INTRODUCTION

Primary brain tumors include any tumors arising in the brain. Primary brain tumors can start from brain cells, meninges, nerves, or glands [1]. Although brain tumor is a rare disease, the incidence of brain tumors is gradually increasing worldwide due to the development of diagnostic technologies and the increased frequency of imaging tests [234]. The prognosis of malignant brain tumors is poor due to its histologic characteristics, however, some benign tumors are located in inoperable areas, and these tumors have similar bad prognosis and require the same economic burden as malignant brain tumors. The Korea Central Cancer Registry (KCCR) started in 1980, and they collected malignant tumors only, excluding benign and borderline tumors. In order to collect benign and borderline brain tumors, the KCCR modified their registration guideline in corporation with the Brain Tumors Registration Committee of the Korean Brain Tumor Society in 2004, and started to register non-malignant brain tumors from year 2005 [5]. The scope of brain tumors included tumors of the meninges, pituitary gland, pineal gland and nerves, as defined in the International Classification of Diseases for Oncology, third edition (ICD-O-3). The first epidemiologic article of primary brain and central nervous system (CNS) tumors of the year of 2005 was published in 2010 [6], and the second paper of year 2010 was published in 2013 [7]. Many registries, such as the Central Brain Tumor Registry of the United States (CBTRUS) and surveillance epidemiology and end results program in USA, collect and disseminate the epidemiology of brain tumor [389101112]. Due to increase of screening with imaging testing, the incidence of brain tumor is increasing and the frequency of tumor diagnosis is changing with time, so the recent changes would be reflected in this paper. This report aims to provide the updated nationwide brain tumor incidence in the Republic of Korea.

MATERIALS AND METHODS

Brain tumor registration

A total of 11,827 brain and CNS patients were registered in 2013 from 396 hospitals. Basic information such as the demographic characteristics of patients, date of diagnosis, tools of diagnosis, topography, and histological type according to the ICD-O-3 were collected by the KCCR [1].

Data processing

Primary brain and CNS tumors with the following ICD-O-3 codes were included in the analysis: brain (C71.0–C71.9), meninges (C70.0–C70.9), spinal cord, cranial nerves and other parts of the CNS (C72.0–C72.9), and pituitary gland, craniopharyngeal duct and pineal gland (C75.1–C75.3). Their histology code was also classified by the ICD-O-3, which are divided into 3 groups: benign, uncertain whether benign or malignant (borderline), and malignant. Histology groupings were based on the classification of the CBTRUS [3]. These groupings were broadly based on the World Health Organization categories for brain tumors. Unclassified tumors include unspecified neoplasms and all other tumors. Unspecified neoplasms refer to cases registered based on death certificates only. The tumors which classified into all other tumors were tumors that did not meet the CBTRUS criteria. The population size used as a denominator to calculate cancer incidence was the mid-year population on 1 July 2013 with modification of the registered population released annually from the Statistics Korea [13]. Childhood tumors were defined as those diagnosed in patients less than 19 years of age.

Statistical analysis

Incidence measures the occurrence of newly diagnosed cases of disease. Crude rate is the rate of disease in an entire population and it is frequently adjusted for age to age-standardized rate to a common standard population, which allows for comparison of rates across different countries with different age structures. We used Segi's world standard population as a standard population in this report [14].

RESULTS

Overall incidence

There were 11,827 newly diagnosed brain tumors from a population of 50.6 million in 2013 (Table 1). The overall crude rate of brain tumors was 23.39 per 100,000 person-years in 2013.
Table 1

Incidence rates of primary brain and CNS tumors by histology and sex, Republic of Korea, 2013

HistologyMaleFemaleTotal
nCRASRnCRASRn%Age*CRASR
Tumors of neuroepithelial tissue8483.352.987613.012.691,60913.652.03.182.82
 Pilocytic astrocytoma250.100.15250.100.19500.412.50.100.17
 Diffuse astrocytoma20.010.0110.000.0130.029.00.010.01
 Anaplastic astrocytoma540.210.18400.160.11940.853.00.190.15
 Unique astrocytoma variants180.070.07160.060.08340.330.50.070.07
 Astrocytoma, NOS650.260.22450.180.141100.947.50.220.18
 Glioblastoma3441.360.992851.130.786295.361.01.240.87
 Oligodendroglioma470.190.15400.160.12870.747.00.170.14
 Anaplastic oligodendroglioma280.110.08310.120.09590.552.00.120.08
 Ependymoma/anaplastic ependymoma340.130.14470.190.15810.746.00.160.15
 Ependymoma variants110.040.04150.060.05260.247.00.050.04
 Mixed glioma250.100.08220.090.07470.444.00.090.07
 Glioma malignant, NOS840.330.32760.300.251601.450.00.320.28
 Choroid plexus90.040.06110.040.05200.233.00.040.05
 Neuroepithelial120.050.0490.040.02210.254.00.040.03
 Non-malignant and malignant neuronal/glial, neuronal and mixed510.200.21540.210.261050.929.00.210.24
 Pineal parenchymal130.050.0590.040.03220.237.50.040.04
 Embryonal/primitive/medulloblastoma260.100.21350.140.30610.55.00.120.25
Tumors of cranial and spinal nerves6742.671.957803.092.101,45412.354.02.882.02
 Nerve sheath, non-malignant and malignant6742.671.957803.092.101,45412.354.02.882.02
 Other tumors of cranial and spinal nerves-----------
Tumors of meninges9963.942.773,48513.798.364,48137.961.08.865.68
 Meningioma9543.772.613,45513.678.264,40937.361.08.725.55
 Other mesenchymal, non-malignant and malignant420.170.16300.120.10720.645.00.140.13
Lymphomas and hemopoietic neoplasms1240.490.34970.380.252211.963.00.440.29
 Lymphoma1240.490.34970.380.252211.963.00.440.29
Germ cell tumors, and cysts920.360.48350.140.181271.118.00.250.34
 Germ cell tumors, cysts and heterotopias920.360.48350.140.181271.118.00.250.34
Tumors of sellar region9113.602.681,3665.404.312,27719.350.04.503.45
 Pituitary8353.302.421,2915.114.052,12618.050.04.203.20
 Craniopharyngioma760.300.26750.300.261511.345.00.300.26
Local extensions from regional tumors60.020.02100.040.03160.144.50.030.02
 Chordoma/chondrosarcoma60.020.02100.040.03160.144.50.030.02
Unclassified tumors7352.912.369073.592.571,64213.953.03.252.46
 Hemangioma1990.790.642390.950.764383.748.00.870.69
 Hemangioblastoma670.270.20450.180.131120.948.50.220.17
 Neoplasm, unspecified4571.811.486132.431.641,0709.056.52.121.56
 All others120.050.05100.040.04220.255.00.040.04
Total4,38617.3413.587,44129.4420.4911,827100.056.023.3917.09

*Median age at diagnosis. CR, crude rate; ASR, age-standardized rate; NOS, not otherwise specified; CNS, central nervous system

The incidence of meningiomas was over 3.5 times higher in females than in males. Nerve sheath tumors, pituitary tumors, andependymomas were also more common in females. On the other hand, germ cell tumors, gliomas (except pilocytic astrocytoma), and lymphomas were more common in males. Unclassified tumors accounted for 13.9% of all CNS tumors. The number of histological confirmed cases were 5,649 (47.8%) (Table 2). Pituitary tumors and nerve sheath tumors, accounted for 19.9% and 13.8% of all histologically confirmed tumors, respectively.
Table 2

The numbers of total and histologically confirmed cases by histological group, Republic of Korea, 2013

Histological groupTotalHistology confirmed
n (%)n (%)
Meningioma4,409 (37.3)1,708 (30.2)
Glioma1,506 (12.7)1,235 (21.9)
Pituitary tumor2,126 (18.0)1,126 (19.9)
Nerve sheath tumor1,454 (12.3)780 (13.8)
Lymphoma221 (1.9)197 (3.5)
Germ cell tumors, cysts and heterotopias127 (1.1)94 (1.7)
Craniopharyngioma151 (1.3)100 (1.8)
Other mesenchymal, non-malignant and malignant72 (0.6)49 (0.9)
Embryonal/primitive/medulloblastoma61 (0.5)59 (1.0)
Hemangioma438 (3.7)110 (1.9)
Choroid plexus20 (0.2)13 (0.2)
Choroid/chondrosarcoma16 (0.1)11 (0.2)
Neoplasm, unspecified1,070 (9.0)58 (1.0)
All others156 (1.3)109 (1.9)
Total11,827 (100.0)5,649 (47.8)

Incidence according to tumor biological behavior

The overall incidence according to biological behavior is shown in Fig. 1. Tumors classified as benign, uncertain, and malignant tumors accounted for 73.2%, 8.8%, and 18.0% of all primary CNS tumors, respectively. The incidence in males was 37.1% and the incidence in females was 62.9%. Benign tumors developed nearly twice more frequently in females than in males (M:F=2,786:5,877). In contrast, the incidences of borderline tumors were noted to be similar.
Fig. 1

Distribution of primary brain and CNS tumors according to sex and behavior, Republic of Korea, 2013. CNS, central nervous system.

Distribution of tumors according to originating site

The incidence according to the originating site is shown in Fig. 2. Meninges (35.2%) were the most common site of primary brain tumors, followed by the brain parenchyma (29.0%), sellar region (21.1%), and cranial and spinal nerves (14.7%). Tumors of the meninges developed more than 3 times frequently in females (Fig. 2). The sellar region tumorsshowed 1.5 times incidence of males than females. The other sites showed no significant differences in incidence according to sex. The overall incidence of primary brain tumors increased with age until the sixth decade. The incidence of each site specific tumor according to age is shown in Fig. 3. Tumorsof the brain parenchyma reached a peak in the sixth decade. Tumors of the meninges seldom occurred in childhood, the incidence of which increased from the third decade and peaked in the sixth decade. Tumors of the nerves peaked in the sixth decade. Sellar tumors increased rapidly in late adolescents and peaked in the sixth decade, which decreased thereafter.
Fig. 2

Distribution of all brain and CNS tumors according to topography, Republic of Korea, 2013. CNS, central nervous system.

Fig. 3

Distribution of primary brain and CNS tumors according to age for selected histology, Republic of Korea, 2013. CNS, central nervous system.

Incidence according to specific histology

Distribution of the tumors according to histology is shownin Fig. 4 and 5. Histologically, tumors of meninges were the most common (37.9%), followed by tumors of the sellar region (19.3%) and neuroepithelial tumors (13.6%).Neuroepithelial tumors of neuroepithelial tissue were composed of astrocytic tumors, oligodendroglial tumors, ependymal tumors, choroid plexus tumors, pineal region tumors, and embryonal tumors. Most of the neuroectodermal tumors were gliomas (93.4%), which accounted for 12.7% of all primary brain tumors. Glioblastomas accounted for 5.3% of all tumors and 41.8% of allgliomas. Among histologically confirmed cases, glioblastomas accounted for 46.2% of all gliomas (Table 3).
Fig. 4

Distribution of brain and CNS tumors according to the histology, Republic of Korea, 2013. NOS, not otherwise specified; CNS, central nervous system.

Fig. 5

Incidence according to sex and histology, Republic of Korea, 2013. NOS, not otherwise specified.

Table 3

The numbers of total and histologically confirmed cases by histological type in gloimas, Republic of Korea, 2013

Histological group in gliomasTotalHistology confirmed
n (%)n (%)
Glioblastoma629 (41.8)570 (46.2)
Astrocytoma, NOS110 (7.3)89 (7.2)
Anaplatic astrocytoma94 (6.2)88 (7.1)
Pilocytic astrocytoma50 (3.3)48 (3.9)
Ependymoma/anaplastic ependymoma/ependymoma variants107 (7.1)100 (8.1)
Oligodendroglioma87 (5.8)83 (6.7)
Anaplastic oligodendroglioma59 (3.9)58 (4.7)
Glioma malignant, NOS160 (10.6)32 (2.6)
Neuroepithelial21 (1.4)12 (1.0)
Mixedglioma47 (3.1)45 (3.6)
Uniqueastrocytomavariants34 (2.3)23 (1.9)
Protoplasmic & fibrillary astrocytoma3 (0.2)3 (0.2)
Non-malignant and malignantneuronal/glial, neuronal and mixed105 (7.0)84 (6.8)
Total1,506 (100.0)1,235 (100.0)

NOS, not otherwise specified

Childhood primary brain tumors according to histology

Distribution of tumors according to histology in childhood is shown in Table 4 and Fig. 6.
Table 4

Incidence rates of primary CNS tumors by histology and sex in childhood (ages 0-19), Republic of Korea, 2013

HistologyMaleFemaleTotal
nCRASRnCRASRnCRASR
Tumors of neuroepithelial tissue1131.982.091102.092.272232.032.18
 Pilocytic astrocytoma150.260.28210.400.43360.330.35
 Anaplastic astrocytoma50.090.1020.040.0470.060.07
 Astrocytoma, NOS60.100.1040.080.07100.090.09
 Glioblastoma90.160.12100.190.17190.170.15
 Ependymoma/anaplastic ependymoma100.170.1930.060.05130.120.12
 Glioma malignant, NOS140.240.2890.170.20230.210.24
 Non-malignant and malignant neuronal/glial, neuronal and mixed140.240.23160.300.33300.270.28
 Embryonal/primitive/medulloblastoma220.380.48310.590.72530.480.60
Tumors of cranial and spinal nerves150.260.20130.250.22280.260.21
Tumors of meninges140.240.22140.270.24280.260.23
Lymphomas and hemopoietic neoplasms10.020.0130.060.0440.040.03
Germ cell tumors, and cysts591.030.89130.250.26720.660.59
Tumors of sellar region350.610.53731.391.151080.980.83
 Pituitary270.470.38621.180.95890.810.65
 Craniopharyngioma80.140.15110.210.20190.170.18
Local extensions from regional tumors---------
Unclassified tumors641.121.09510.970.971151.051.03
Total3015.275.032775.275.175785.275.10

CR, crude rate; ASR, age-standardized rate; NOS, not otherwise specified; CNS, central nervous system

Fig. 6

Distribution of primary brain and CNS tumors according to histology in children, Republic of Korea, 2013. CNS, central nervous system; NOS, not otherwise specified.

Children numbering 578 under 19 years of age were diagnosed with brain tumors in 2013, and crude rates of primary brain tumors in children was 5.27 per 100,000 person-years. The incidence was slightly higher in females (5.17) than in males (5.03). The most common histology in children included neuroepithelial tumors, germ cell tumors, and tumors of thesellar region. Neuroepithelial tumors accounted for 38.6% of all tumors in children. Embryonal/primitive/medulloblastoma was the most common tumor among neuroepithelial tumors in children. Glioblastomas accounted for only 3.3% of all primary brain tumors in children.

DISCUSSION

This is the third nationwide report on primary brain and CNS tumors, encompassing benign, borderline, and malignant tumors in the Republic of Korea. Compared to two previous reports of 2005 and 2010, crude rates for brain and CNS tumors increased from 11.7 per 100,000 in 2005 [6], to 20.1 in 2010 [7], and 23.4 in 2013. Age-standardized rates also increased from 10.2 in 2015, to 15.7 in 2010, and 17.1 in 2010. The incidences of all histological types increased in 2013 compared to 2010, however, most of this increase was due to benign tumors, including tumors of the cranial nerves, meninges, andsellar. The increased frequency of MRI scans could be a main reason for benign tumors increase. Age-standardized rate of malignant brain tumors was 2.9 per 100,000, and slightly lower than the worldwide incidence rate (3.4 per 100,000), according to Globocan 2012 [15]. Among children, the age-standardized rate of brain tumors also increased from 3.72 in 2005 to 5.00 in 2010, and 5.10 in 2013. In conclusion, we updated the nationwide statistics of brain and CNS tumors in the Republic of Korea. Updated incidence of brain tumors will help to assess disease burden, facilitate etiologic studies, and establish cancer prevention and control strategies.
  10 in total

1.  Report of Brain Tumor Registry of Japan (1969-1996).

Authors: 
Journal:  Neurol Med Chir (Tokyo)       Date:  2003-09       Impact factor: 1.742

2.  The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry.

Authors:  Adelheid Wöhrer; Thomas Waldhör; Harald Heinzl; Monika Hackl; Johann Feichtinger; Ulrike Gruber-Mösenbacher; Andreas Kiefer; Hans Maier; Reinhard Motz; Angelika Reiner-Concin; Bernd Richling; Carmen Idriceanu; Michael Scarpatetti; Roland Sedivy; Hans-Christian Bankl; Wolfgang Stiglbauer; Matthias Preusser; Karl Rössler; Johannes Andreas Hainfellner
Journal:  J Neurooncol       Date:  2009-06-28       Impact factor: 4.130

3.  Trend of brain tumor incidence by histological subtypes in Japan: estimation from the Brain Tumor Registry of Japan, 1973-1993.

Authors:  Satoshi Kaneko; Kazuhiro Nomura; Takesumi Yoshimura; Naohito Yamaguchi
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

4.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Chaturia Rouse; Yanwen Chen; Jacqueline Dowling; Yingli Wolinsky; Carol Kruchko; Jill Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

5.  French brain tumor data bank: methodology and first results on 10,000 cases.

Authors:  Luc Bauchet; Valérie Rigau; Hélène Mathieu-Daudé; Dominique Figarella-Branger; Delphine Hugues; Loreleï Palusseau; Fabienne Bauchet; Michel Fabbro; Chantal Campello; Laurent Capelle; Anne Durand; Brigitte Trétarre; Didier Frappaz; Dominique Henin; Philippe Menei; Jérome Honnorat; François Segnarbieux
Journal:  J Neurooncol       Date:  2007-04-13       Impact factor: 4.130

6.  Epidemiology of primary brain and central nervous system tumors in Korea.

Authors:  Chang-Hyun Lee; Kyu-Won Jung; Heon Yoo; Sohee Park; Seung Hoon Lee
Journal:  J Korean Neurosurg Soc       Date:  2010-08-31

7.  Temporal trends in incidence of primary brain tumors in the United States, 1985-1999.

Authors:  Sara Hoffman; Jennifer M Propp; Bridget J McCarthy
Journal:  Neuro Oncol       Date:  2006-01       Impact factor: 12.300

8.  Trends in incidence of brain and central nervous system tumors in Norway, 1970-1999.

Authors:  T B Johannesen; E Angell-Andersen; S Tretli; F Langmark; K Lote
Journal:  Neuroepidemiology       Date:  2004 May-Jun       Impact factor: 3.282

9.  Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database.

Authors:  Hai-Rim Shin; Young-Joo Won; Kyu-Won Jung; Hyun-Joo Kong; Seon-Hee Yim; Jung-Kyu Lee; Hong-In Noh; Jong-Koo Lee; Paola Pisani; Jae-Gahb Park
Journal:  Cancer Res Treat       Date:  2005-12-31       Impact factor: 4.679

10.  An updated nationwide epidemiology of primary brain tumors in republic of Korea.

Authors:  Kyu-Won Jung; Johyun Ha; Seung Hoon Lee; Young-Joo Won; Heon Yoo
Journal:  Brain Tumor Res Treat       Date:  2013-04-30
  10 in total
  31 in total

1.  Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.

Authors:  Taeryool Koo; Do Hoon Lim; Ho Jun Seol; Yun-Sik Dho; Il Han Kim; Jong Hee Chang; Jeongshim Lee; Tae-Young Jung; Ho-Shin Gwak; Kwan Ho Cho; Chang-Ki Hong; Ik Jae Lee; El Kim; Jin Hee Kim; Yong-Kil Hong; Hong Seok Jang; Chae-Yong Kim; In Ah Kim; Sung Hwan Kim; Young Il Kim; Eun-Young Kim; Woo Chul Kim; Semie Hong
Journal:  J Neurooncol       Date:  2018-08-10       Impact factor: 4.130

2.  Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.

Authors:  Taeryool Koo; Do Hoon Lim; Ho Jun Seol; Chul-Kee Park; Il Han Kim; Jong Hee Chang; Jeongshim Lee; Shin Jung; Ho-Shin Gwak; Kwan Ho Cho; Chang-Ki Hong; Ik Jae Lee; El Kim; Jin Hee Kim; Yong-Kil Hong; Hong Seok Jang; Chae-Yong Kim; In Ah Kim; Sung Hwan Kim; Young Il Kim; Eun-Young Kim; Woo Chul Kim; Semie Hong
Journal:  J Neurooncol       Date:  2018-03-23       Impact factor: 4.130

Review 3.  An international study evaluating the epidemiology of intracranial germ cell tumors in the native versus immigrant Japanese populations: the need for an international registry.

Authors:  Ashley S Plant-Fox; Tomonari Suzuki; Rosdali Y Diaz Coronado; Sidnei Epelman; Luiz Sakamoto; Sylvia Cheng; Takaaki Yanagisawa; Bernard Rosner; Susan N Chi; Mark W Kieran
Journal:  J Neurooncol       Date:  2022-08-02       Impact factor: 4.506

4.  A rare case of intraparenchymal subependymoma in a child.

Authors:  Kyeong-O Go; Minji Lee; Yeji Lim; Kyu Sang Lee; Gheeyoung Choe; Chae-Yong Kim
Journal:  Childs Nerv Syst       Date:  2020-08-17       Impact factor: 1.475

5.  Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.

Authors:  Chae-Yong Kim; Sun Ha Paek; Do-Hyun Nam; Jong-Hee Chang; Yong-Kil Hong; Jeong Hoon Kim; Oh Lyong Kim; Se-Hyuk Kim
Journal:  J Neurooncol       Date:  2020-02-04       Impact factor: 4.130

6.  Hypo-trimethylation of Histone H3 Lysine 4 and Hyper-tri/dimethylation of Histone H3 Lysine 27 as Epigenetic Markers of Poor Prognosis in Patients with Primary Central Nervous System Lymphoma.

Authors:  Hoon Gi Kim; Minseok S Kim; Young Sam Lee; Eun Hee Lee; Dae Cheol Kim; Sung-Hun Lee; Young Zoon Kim
Journal:  Cancer Res Treat       Date:  2021-11-17       Impact factor: 5.036

7.  Efficacy of Cytokine-Induced Killer Cell Immunotherapy for Patients With Pathologically Pure Glioblastoma.

Authors:  Myung-Hoon Han; Jae Min Kim; Jin Hwan Cheong; Je Il Ryu; Yu Deok Won; Gun He Nam; Choong Hyun Kim
Journal:  Front Oncol       Date:  2022-04-08       Impact factor: 5.738

Review 8.  The Overview of Practical Guidelines for Gliomas by KSNO, NCCN, and EANO.

Authors:  Young Zoon Kim; Chae-Yong Kim; Do Hoon Lim
Journal:  Brain Tumor Res Treat       Date:  2022-04

9.  The Clinical Outcome of Hydroxyurea Chemotherapy after Incomplete Resection of Atypical Meningiomas.

Authors:  Jungook Kim; Kyu Hong Kim; Young Zoon Kim
Journal:  Brain Tumor Res Treat       Date:  2017-10-31

Review 10.  Prevalence of incidental meningiomas and gliomas on MRI: a meta-analysis and meta-regression analysis.

Authors:  Satoshi Nakasu; Akifumi Notsu; Yoko Nakasu
Journal:  Acta Neurochir (Wien)       Date:  2021-07-06       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.